EICHOR
● Active Not Recruiting
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Condition: Advanced or Metastatic Non-small Cell Lung Cancer · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (187)
| City of Hope Duarte | Duarte, California, United States | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | — |
| City of Hope Long Beach Elm | Long Beach, California, United States | — |
| National Jewish Health | Denver, Colorado, United States | — |
| Baptist Lynn Cancer Institute | Boca Raton, Florida, United States | — |
| Orlando Health | Orlando, Florida, United States | — |
| University of Kansas | Kansas City, Kansas, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Astera Cancer Care | East Brunswick, New Jersey, United States | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | — |
| NYU Langone Health Laura and Isaac Perlmutter Cancer Center | New York, New York, United States | — |
| Montefiore Medical Center | The Bronx, New York, United States | — |
+ 175 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.